touchONCOLOGY joins Dr Shibani Nicum (University College London, UK) at ESMO 2021 to present the first results of the OCTOVA trial of olaparib compared to weekly paclitaxel or olaparib plus cediranib in patients with platinum-resistant ovarian cancer.
1. What are the unmet needs in the treatment of ovarian cancer patients who relapse within 12 months of platinum-based chemotherapy? 00:18-01:00)
2. What is the rationale for combining olaparib and cediranib in this indication? (01:08-02:26)
3. Could you tell us a little about the aims, design and patient stratification of the OCTOVA trial? (02:26-03:55)
4. What were the efficacy and safety findings of the trial? (03:55-05:42)
5. What were the conclusions of the investigators, and what future studies are planned? (05:42-06:30)
Disclosures: Shibani Nicum disclosures consulting and advisory services, speaking or writing engagements, public presentations for AstraZeneca, GSK and Clovis, and academic funding from AstraZeneca.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the ESMO 2021 Annual Meeting.
Share this Video
Related Videos In Ovarian Cancer
Paul DiSilvestro, ESMO 2022: SOLO1/GOG-3004 trial – Olaparib for the treatment of advanced ovarian cancer – Overall survival findings at 7 years
The Phase III SOLO1/GOG-3004 trial (NCT01844986), investigated maintenance olaparib, which provided sustained benefit beyond the end of treatment in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation. Prof. Paul DiSilvestro (Brown University, Providence, RI, USA) joins touchONCOLOGY to discuss the efficacy and safety of maintenance olaparib, and overall survival findings at 7 years. […]
Ruth Perets, AACR 2022: Vibostolimab/Pembrolizumab Coformulation for the Treatment of Ovarian Cancer Naive to PD-1/PD-L1 Inhibitors
We were delighted to speak with Dr. Ruth Perets (Rambam Health Care Campus, Haifa, Israel) about the efficacy and safety findings of the phase 1 study comparing vibostolimab (vibo) plus pembrolizumab (pembro) given sequentially to the coformulation of vibo/pembro in ovarian cancer naive to PD-1/PD-L1 inhibitors. The abstract ‘Safety and efficacy of vibostolimab (vibo) plus […]
Domenica Lorusso, ESMO 2021: Relacorilant in Combination with Nab-paclitaxel for Patients with Recurrent Platinum-resistant Ovarian Cancer
touchONCOLOGY joins Dr Domenica Lorusso (Rome, Italy), to discuss the improvements in progression-free survival in patients with recurrent platinum-resistant ovarian cancer using relacorilant in combination with nab-paclitaxel. (NCT03776812) Question Please summarise the randomized, open-label, phase II study presented at ESMO 2021 exploring progression-free survival in patients with recurrent platinum-resistant ovarian cancer using relacorilant, a selective […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!